Stueland Katherine 4

What Happened

• Katherine Stueland, CEO of GeneDx Holdings Corp. (WGS), acquired 3,404 shares of the company's Class A common stock on March 6, 2026.
• Purchase price was $88.11 per share, for a total cost of $299,926. The Form 4 classifies the transaction as an acquisition/award (code A), not a sale.

Key Details

• Transaction date and price: March 6, 2026 — 3,404 shares at $88.11/share.
• Total value: $299,926 (3,404 × $88.11).
• Shares owned after the transaction: not specified in the filing.
• Filing date: Form 4 filed March 9, 2026 (reported within the standard Form 4 reporting window).
• Footnote: The shares were acquired directly from the issuer under a Subscription Agreement dated March 6, 2026 and the transaction was exempt under Rule 16b-3(d); the purchase price equals the closing price on March 6, 2026.

Context

• This was a direct purchase from the company (not an open-market buy or an option exercise). Purchases by insiders can be more informative to investors than routine sales, but the filing provides only transaction mechanics (no stated motivation).